immunodeficiency virus type 1; HBV, hepatitis B virus; HCV, hepatitis C virus; IAV, influenza A virus; DGV, dengue virus; PF, Plasmodium falciparum; TB, Mycobacterium tuberculosis; Others, peptides derived from other organisms (peptides with no source organism annotation were excluded). Supplementary Figure 2 . Correlograms of the minimal sets of features selected as the most predictive of epitope immunogenicity. Eighty percent of the entire epitope dataset was randomly extracted, and feature importance was estimated by training a random forest classifier. Based on the feature importance estimates, top 100 features were selected. This selection process was repeated ten times, and the consensus feature sets were generated for both MHC-I and MHC-II epitopes. Classification performances were evaluated using the prediction scores (rescaled to 0-1 range) derived from the IEDB Class I Immunogenicity Tool (34) (http://tools.iedb.org/immunogenicity/) with default settings. Note that peptides used for training the model in the original paper were not excluded from prediction, which theoretically overestimates its predictive performance. Figure 6 . Improvement of predictive performances of immunogenicity scores for transitional peptides by integrating the neighbor network architectures in sequence space. Predictive performances of the immunogenicity scores of (A) MHC-I-and (B) MHC-II-restricted transitional peptides, i.e., peptides with at least one neighbor of opposite immunogenicity annotation in our dataset, were evaluated. We identified 1,360 and 976 transitional peptides for MHC-I and MHC-II, respectively. We expanded their neighbor networks by computing immunogenicity scores for 232,723 and 292,437 all possible single-aa mutants of transitional MHC-I-and MHC-II-restricted peptides, respectively. Original, original immunogenicity scores; Overall, mean immunogenicity scores of all neighbors. Cluster, mean immunogenicity scores of neighbors assigned to the cluster containing the parent peptide. Others, original immunogenicity scores for peptides with no evidence of immune transition (shown for comparison purpose).
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